A new study finds four factors that may make it more likely for some people to experience successful weight loss from using ...

MariTide, a groundbreaking weight loss medication, shows 16% weight reduction in trials. Learn about this promising monthly ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

Linear relationship seen for waist circumference, BP; reduction in HOMA-IR, hemoglobin A1c seen with modest weight reduction.

Monthly weight-loss shots on the horizon! Learn about new drugs like MariTide and why Black participation in clinical trials ...

Pennington Biomedical researchers have contributed to a study highlighting the crucial role of cysteine in regulating ...

Efsitora matched or exceeded A1C reductions seen with daily basal insulin across three trials, while orforglipron demonstrated benefits for blood sugar control and weight loss at higher doses.

To put these metabolic improvements into perspective, 14-mg daily oral semaglutide (Rybelsus) yielded a 1.5% HbA1c reduction and a 4.9 kg (10.8 lbs) weight loss after 26 weeks in the PIONEER-1 trial.

Findings from the MariTide Phase 2 Trial demonstrating weight loss and A1C reduction in groups with and without type 2 diabetes were presented as a late-breaking symposia at this year's Scientific ...

Eli Lilly says new data shows promising results for GLP-1 pill Drug maker Eli Lilly says data from a late-stage trial showed a reduction in weight of almost 8% in people with Type 2 diabetes.

Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea.

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with ...